[go: up one dir, main page]

PE20081897A1 - 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas - Google Patents

3-imidazolil-indoles para el tratamiento de enfermedades proliferativas

Info

Publication number
PE20081897A1
PE20081897A1 PE2008000554A PE2008000554A PE20081897A1 PE 20081897 A1 PE20081897 A1 PE 20081897A1 PE 2008000554 A PE2008000554 A PE 2008000554A PE 2008000554 A PE2008000554 A PE 2008000554A PE 20081897 A1 PE20081897 A1 PE 20081897A1
Authority
PE
Peru
Prior art keywords
alkyl
chloro
halogen
indol
imidazol
Prior art date
Application number
PE2008000554A
Other languages
English (en)
Inventor
Andreas Boettcher
Nicole Buschmann
Jorg Kallen
Keiichi Masuya
Andrea Vaupei
Pascal Furet
Jean-Marc Groell
Joanna Hergovich Lisztwan
Lorenz Mayr
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38328915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081897(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20081897A1 publication Critical patent/PE20081897A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 3-IMIDAZOLIL-INDOL DE FORMULA (I) DONDE R1 ES ALQUILO(C1-C20), ALQUENILO(C2-C20), ALQUINILO(C2-C20), ARILO(C6-C18), ENTRE OTROS; R2 ES ALQUILO(C1-C20), ALQUENILO(C2-C20), ALQUINILO(C2-C20), HETEROCICLILO DE 3 A 24 MIEMBROS, ENTRE OTROS; R3 ES H, HALOGENO, ALQUILO(C1-C20), ALQUINILO(C2-C20), CN, ENTRE OTROS; R4 ES H, HALOGENO, ALQUENILO(C2-C20), CARBOXILO, ENTRE OTROS; RA ES H, ALQUILO(C1-C20) O ACILO; X ES H, ALQUILO(C1-C7), HALOALQUILO(C1-C7), HALOGENO, ENTRE OTROS; Y ES ALQUILO(C1-C7), ALCOXILO(C1-C7), HALOGENO, CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 6-CLORO-3-[3-(4-CLORO-BENCIL)-5-FENIL-3H-IMIDAZOL-4-IL]-1H-INDOL, (2-MORFOLIN-4-IL-ETIL)-AMIDA DEL ACIDO 6-CLORO-3-[3-(4-CLORO-BENCIL)-5-FENIL-3H-IMIDAZOL-4-IL]-1H-INDOL-2-CARBOXILICO, ETIL-ESTER DEL ACIDO 6-CLORO-3-[3-(4-CLORO-BENCIL)-5-FENIL-3H-IMIDAZOL-4-IL]-1H-INDOL-2-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA INTERACCION ENTRE P53 O VARIANTES DE LA MISMA CON EL ONCOGEN DIMINUTO DOBLE DE MURINO MDM2 O MDM4 SIENDO UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, LUPUS ERITEMATOSO SISTEMICO, ESCLEROSIS MULTIPLE, ASMA, OSTEOSARCOMA
PE2008000554A 2007-03-29 2008-03-27 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas PE20081897A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07105269 2007-03-29

Publications (1)

Publication Number Publication Date
PE20081897A1 true PE20081897A1 (es) 2009-02-09

Family

ID=38328915

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000554A PE20081897A1 (es) 2007-03-29 2008-03-27 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas

Country Status (27)

Country Link
US (1) US8053457B2 (es)
EP (1) EP2142535A2 (es)
JP (1) JP2010522723A (es)
KR (1) KR20090122403A (es)
CN (1) CN101679382A (es)
AR (1) AR065860A1 (es)
AU (1) AU2008234954B9 (es)
BR (1) BRPI0810082A2 (es)
CA (1) CA2682483A1 (es)
CL (1) CL2008000899A1 (es)
CR (1) CR11019A (es)
DO (1) DOP2009000229A (es)
EA (1) EA200901212A1 (es)
EC (1) ECSP099660A (es)
GT (1) GT200900256A (es)
IL (1) IL200862A0 (es)
MA (1) MA31260B1 (es)
MX (1) MX2009010413A (es)
NI (1) NI200900177A (es)
PA (1) PA8774001A1 (es)
PE (1) PE20081897A1 (es)
SM (1) SMP200900085B (es)
TN (1) TN2009000388A1 (es)
TW (1) TW200843746A (es)
UY (1) UY30987A1 (es)
WO (1) WO2008119741A2 (es)
ZA (1) ZA200906210B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5132673B2 (ja) * 2006-04-07 2013-01-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のモジュレーターとしてのインドールおよびベンゾイミダゾール
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
WO2009158375A1 (en) * 2008-06-25 2009-12-30 Abbott Laboratories Aza-cylic indole- 2 -carboxamides and methods of use thereof
ES2646630T3 (es) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Lipidoides aminoalcohólicos y usos de los mismos
JP5520236B2 (ja) 2009-01-16 2014-06-11 第一三共株式会社 プロリン環構造を有するイミダゾチアゾール誘導体
JP2012102017A (ja) * 2009-03-03 2012-05-31 Astellas Pharma Inc インドール化合物
EP2419408A4 (en) * 2009-04-16 2012-09-05 Msd Kk 3-ARYL OR HETEROARYL-SUBSTITUTED INDOOR DERIVATE
KR20120099462A (ko) 2009-11-12 2012-09-10 더 리젠츠 오브 더 유니버시티 오브 미시건 스피로-옥신돌 ｍｄｍ2 길항제
WO2011106650A2 (en) * 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US9187441B2 (en) 2010-09-08 2015-11-17 University of Pittsburgh—of the Commonwealth System of Higher Education p53-Mdm2 antagonists
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
SG190230A1 (en) 2010-11-12 2013-06-28 Univ Michigan Spiro-oxindole mdm2 antagonists
US20120202794A1 (en) * 2011-01-24 2012-08-09 Pharmasset, Inc. Compounds
SG10201601802YA (en) 2011-03-10 2016-04-28 Daiichi Sankyo Co Ltd Dispiropyrrolidine derivatives
CN102702066A (zh) * 2011-03-28 2012-10-03 苏州百灵威超精细材料有限公司 一种用于合成抗癌和减肥药物中间体6-氯-5-氟吲哚的制备新方法
DK2691443T3 (da) 2011-03-28 2021-05-03 Massachusetts Inst Technology Konjugerede lipomerer og anvendelser af disse
US8629141B2 (en) 2011-05-11 2014-01-14 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
WO2012176123A1 (en) * 2011-06-22 2012-12-27 Novartis Ag 3 - imidazolyl- indoles for the treatment of proliferative diseases
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
US20140335074A1 (en) 2011-12-13 2014-11-13 Buck Institute For Research On Aging Methods for improving medical therapies
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
EP2882706A1 (en) 2012-08-13 2015-06-17 Massachusetts Institute of Technology Amine-containing lipidoids and uses thereof
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
JP6387013B2 (ja) 2012-12-20 2018-09-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｄｍ２阻害薬としての置換されたイミダゾピリジン類
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
CA2939121C (en) 2014-01-28 2020-11-24 Mayo Foundation For Medical Education And Research Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US11331328B2 (en) 2014-05-05 2022-05-17 Bioventures, Llc Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
EP3164401B1 (en) 2014-07-03 2018-12-26 Boehringer Ingelheim International GmbH New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
WO2016014625A1 (en) 2014-07-22 2016-01-28 Board Of Trustees Of The University Of Arkansas Compositions and methods for selectively depleting senescent cells
US20160052938A1 (en) 2014-08-21 2016-02-25 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
JP2018502846A (ja) 2014-12-26 2018-02-01 ダウ グローバル テクノロジーズ エルエルシー 有機化合物、及び有機化合物を含む有機層を備える電子デバイス
KR102595395B1 (ko) 2015-02-20 2023-10-27 다이이찌 산쿄 가부시키가이샤 암의 병용 치료법
EP3284466A4 (en) 2015-04-13 2018-12-05 Daiichi Sankyo Company, Limited Treatment method combining mdm2 inhibitor and btk inhibitor
PE20180610A1 (es) 2015-06-22 2018-04-09 Bayer Pharma AG CONJUGADOS DE LIGADOR-PRINCIPIO ACTIVO (ADCs) Y CONJUGADOS DE LIGADOR-PROFARMACO (APDCs) CON GRUPOS ENZIMATICAMENTE ESCINDIBLES
JOP20160198B1 (ar) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX377009B (es) 2015-10-09 2025-03-07 Boehringer Ingelheim Int Nuevos compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53.
KR102387316B1 (ko) 2016-04-06 2022-04-15 더 리젠츠 오브 더 유니버시티 오브 미시간 Mdm2 단백질 분해제
WO2017176958A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
JP6936498B2 (ja) 2016-04-21 2021-09-15 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用
CN105906610B (zh) * 2016-05-24 2018-10-23 绍兴文理学院 一种3-（4-苯基-1h-咪唑-5-基）-1h-吲哚衍生物及其制备方法和应用
EP3272745B1 (en) * 2016-07-21 2019-06-26 Instytut Farmakologii Polskiej Akademii Nauk Imidazolyl-substituted indole derivatives binding 5-ht7 serotonin receptor and pharmaceutical compositions thereof
EP3527226A4 (en) 2016-10-17 2020-06-17 Daiichi Sankyo Company, Limited COMBINATION THERAPY PROCEDURE WITH MDM2 INHIBITOR AND DNA METHYL TRANSFERASE INHIBITOR
TW201831477A (zh) 2016-11-28 2018-09-01 瑞士商赫孚孟拉羅股份公司 噁二唑酮瞬時受體電位通道抑制劑
WO2018114578A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
CN114874209B (zh) 2017-03-07 2024-08-06 豪夫迈·罗氏有限公司 噁二唑瞬时受体电位通道抑制剂
EP4368200A3 (en) 2017-04-05 2024-07-17 Boehringer Ingelheim International GmbH Anticancer combination therapy
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JP7281822B2 (ja) * 2017-05-26 2023-05-26 ラトガーズ、ザ ステイト ユニバーシティ オブ ニュージャージー 細菌の排出ポンプ阻害剤
EP3743069B1 (en) 2018-01-22 2025-08-06 BioVentures, LLC Bcl-2 proteins degraders for cancer treatment
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
US12084423B2 (en) 2018-05-18 2024-09-10 Bioventures, Llc Piperlongumine analogues and uses thereof
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
EP3931188B1 (en) * 2019-02-26 2023-08-30 Boehringer Ingelheim International GmbH New isoindolinone substituted indoles and derivatives as ras inhibitors
WO2020176983A1 (en) 2019-03-01 2020-09-10 Ontario Institute For Cancer Research (Oicr) Amide-based proteolysis modulators of b-rapidly accelerated fibrosarcoma (braf) and associated uses
EP4267564A1 (en) * 2020-12-22 2023-11-01 Novartis AG Indole derivatives useful in treating conditions associated with cgas
WO2022204235A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
CN117510416A (zh) * 2023-11-06 2024-02-06 浙江普洛康裕制药有限公司 一种(2R,5S)-4-Boc-2,5-二甲基哌嗪的制备方法
PL447976A1 (pl) * 2024-03-11 2025-09-15 Celon Pharma Spółka Akcyjna Pochodna imidazolo-indolowa wiążąca się z receptorem serotoninowym 5-HT7, kompozycja farmaceutyczna zawierająca tę pochodną, zastosowania pochodnej i kompozycji oraz produkt pośredni do wytwarzania pochodnej imidazolo-indolowej
WO2025231011A1 (en) * 2024-05-01 2025-11-06 Omniab, Inc. Heteroarylindole inhibitors of apol-1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19948417A1 (de) * 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
JP2002114780A (ja) * 2000-10-11 2002-04-16 Taisho Pharmaceut Co Ltd ４−（３−インドリル）イミダゾール誘導体
EA014445B1 (ru) 2005-02-22 2010-12-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Низкомолекулярные ингибиторы mdm2 и их применения
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives

Also Published As

Publication number Publication date
US20100125064A1 (en) 2010-05-20
WO2008119741A3 (en) 2008-12-04
TN2009000388A1 (en) 2010-12-31
NI200900177A (es) 2010-09-09
PA8774001A1 (es) 2008-11-19
AU2008234954B9 (en) 2012-02-02
CL2008000899A1 (es) 2009-02-20
UY30987A1 (es) 2008-10-31
CN101679382A (zh) 2010-03-24
AR065860A1 (es) 2009-07-08
AU2008234954A1 (en) 2008-10-09
CR11019A (es) 2009-10-20
SMP200900085B (it) 2010-11-12
BRPI0810082A2 (pt) 2014-10-21
EA200901212A1 (ru) 2010-04-30
IL200862A0 (en) 2010-05-17
SMAP200900085A (it) 2010-01-19
MX2009010413A (es) 2009-10-20
MA31260B1 (fr) 2010-03-01
ECSP099660A (es) 2009-10-30
TW200843746A (en) 2008-11-16
GT200900256A (es) 2010-03-15
WO2008119741A2 (en) 2008-10-09
ZA200906210B (en) 2010-05-26
CA2682483A1 (en) 2008-10-09
US8053457B2 (en) 2011-11-08
EP2142535A2 (en) 2010-01-13
AU2008234954B2 (en) 2011-10-27
DOP2009000229A (es) 2009-10-31
KR20090122403A (ko) 2009-11-27
JP2010522723A (ja) 2010-07-08

Similar Documents

Publication Publication Date Title
PE20081897A1 (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
PE20131197A1 (es) Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
RU2434853C2 (ru) Новые конденсированные производные пиррола
PE20090157A1 (es) Derivados de pirimidinona como moduladores del receptor acoplado a proteina g 119 (gpr119)
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
EA201270676A1 (ru) Полиморфная, кристаллическая и мезофазная формы 2-(5-бром-4-(4-циклопропилнафталинил-1-ил)-4н-1,2,4-триазол-3- илтио)ацетата натрия и их применение
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
PE20090183A1 (es) Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5
PE20090695A1 (es) Derivados de pirimidindiona como agonistas del receptor de acido nicotinico
PE20140245A1 (es) Compuesto de furo[3,2-d]pirimidina
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20070419A1 (es) Derivados de benzoquinazolina
PE20120691A1 (es) Derivados de n1-sulfonil-5-fluoropirimidinona
PE20110368A1 (es) Moduladores de mif
PE20161443A1 (es) Compuestos
PE20070585A1 (es) Derivados de sulfonamida como activadores de glucoquinasa
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
PE20130158A1 (es) Inhibidores no nucleosidicos de la transcriptasa inversa
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
PE20140610A1 (es) Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
PE20091653A1 (es) Derivados sustituidos de pirazol y su uso
AR070797A1 (es) Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes

Legal Events

Date Code Title Description
FC Refusal